You are viewing: Rest Of Europe Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The Rest Of Europe Nuclear Medicine Market was valued at $523.4 Million in 2025 and projected to reach to $1057.3 Million by 2030, representing a compound annual growth rate of 15.1%. Rest Of Europe's nuclear medicine market is positioned for substantial growth over the forecast period, driven by demographic pressures, healthcare modernization, and increasing clinical adoption of nuclear imaging technologies.

Rest Of Europe Nuclear Medicine Market Trends and Insights

  • This 15.1% compound annual growth rate reflects increasing adoption of diagnostic imaging and therapeutic nuclear medicine procedures across the region.
  • Rest Of Europe is benefiting from aging populations, rising prevalence of chronic diseases, and modernization of healthcare infrastructure that drives demand for advanced nuclear medicine technologies. The market in Rest Of Europe is characterized by growing investment in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) systems, alongside expanding radiopharmaceutical production capabilities.
  • Rest Of Europe's healthcare systems are increasingly recognizing nuclear medicine's clinical value in oncology, cardiology, and neurology applications.
  • Between 2025 and 2030, Rest Of Europe is expected to see significant capital expenditure in nuclear medicine facilities and enhanced regulatory frameworks supporting radiopharmaceutical development and deployment..

Key Market Statistics

  • CAGR (2025-2030) 15.1% CAGR
  • Market Size, 2025 ~USD 523.4 Million
  • Forecast, 2030 ~USD 1057.3 Million
  • Country Rest Of Europe

Rest Of Europe Nuclear Medicine Market Overview

Rapid Market Expansion :

Rest Of Europe's nuclear medicine market is projected to nearly double from $523.4 million in 2025 to $1,057.3 million by 2030, driven by a strong 15.1% CAGR reflecting accelerating adoption of advanced diagnostic and therapeutic procedures.

Aging Population Demographics :

Rest Of Europe faces significant demographic shifts with aging populations driving increased demand for nuclear medicine diagnostics, particularly for oncology, cardiology, and neurology applications where early detection is critical.

Healthcare Infrastructure Investment :

Regional governments and private healthcare providers are investing heavily in nuclear medicine facilities and equipment, improving accessibility to PET/CT, SPECT, and therapeutic nuclear medicine across Rest Of Europe's diverse healthcare systems.

Chronic Disease Prevalence :

Rising incidence of cancer, cardiovascular diseases, and neurological disorders in Rest Of Europe is fueling demand for nuclear medicine imaging and targeted therapeutic interventions, supporting sustained market growth through 2030.

Rest Of Europe Nuclear Medicine Market Dynamics

  • The region's diverse healthcare landscapes present opportunities for both diagnostic imaging expansion and therapeutic nuclear medicine applications, particularly in oncology and cardiology segments. Key growth catalysts include aging populations requiring advanced diagnostic capabilities, rising chronic disease prevalence, and ongoing investments in healthcare infrastructure across Rest Of Europe.
  • Market players should focus on regulatory compliance across multiple jurisdictions, partnerships with regional healthcare providers, and development of cost-effective solutions tailored to varying healthcare system maturity levels throughout the region..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Rest Of Europe's nuclear medicine market will grow from $523.4M (2025) to $1,057.3M (2030) at a 15.1% CAGR
    • Rest Of Europe is investing heavily in PET/SPECT imaging infrastructure and radiopharmaceutical production capacity
    • Aging demographics and chronic disease prevalence are primary growth drivers for Rest Of Europe's nuclear medicine adoption
    • Rest Of Europe's regulatory environment is increasingly supportive of nuclear medicine innovation and therapeutic applications

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2039
    Growth Rate CAGR of 15.1% from 2025 to 2039
    Largest Segment DIAGNOSTIC PROCEDURES (Procedure)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2039)
    Segments Covered Type, Application, Procedure, End User

    Rest Of Europe Nuclear Medicine Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Bone Metastasis
    • Bone Scans
    • Brachytherapy Isotopes
    • Cardiology
    • Cs-131
    • Diagnostic Nuclear Medicine
    • Endocrine Tumors
    • F-18
    • Ga-67
    • I-123
    • I-125
    • I-131
    • Ir-192
    • Lu-177
    • Lymphoma
    • Neurology
    • Oncology
    • Other Beta Emitters
    • Other Brachytherapy Isotopes
    • Other Pet Applications
    • Other Pet Radiopharmaceuticals
    • Other Spect Applications
    • Other Spect Radiopharmaceuticals
    • Other Therapeutic Applications
    • Pd-103
    • Pet Applications
    • Pet Procedures
    • Pet Radiopharmaceuticals
    • Pulmonary Scans
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Applications
    • Spect Procedures
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Thyroid
    • Tl-201
    • Y-90

    By Application

    • Diagnostic Applications
    • Therapeutic Applications

    By Procedure

    • Diagnostic Procedures
    • Therapeutic Procedures

    By End User

    • Academic & Research Institutes
    • Diagnostic & Imaging Centers
    • Hospitals
    • Other End Users

    Target Audience

    • Medical Device Manufacturers : Nuclear medicine equipment and imaging system providers need Rest Of Europe-specific market data to identify growth opportunities, optimize product portfolios, and develop region-tailored commercialization strategies for PET/CT and SPECT systems.
    • Healthcare Investors & PE Firms : Investment professionals require detailed Rest Of Europe market analysis to evaluate acquisition targets, assess growth potential of nuclear medicine providers, and make informed capital allocation decisions in the region's expanding healthcare sector.
    • Hospital & Imaging Center Operators : Healthcare facility managers need Rest Of Europe market insights to justify nuclear medicine department investments, benchmark performance against regional peers, and plan service expansion aligned with demographic and disease trends.
    • Pharmaceutical & Radiopharmaceutical Companies : Drug developers and radiopharmaceutical manufacturers require Rest Of Europe-specific demand forecasts to guide R&D investments, clinical trial planning, and commercialization strategies for diagnostic and therapeutic nuclear medicine products.
    • Healthcare Consultants & Analysts : Strategy consultants and market analysts need comprehensive Rest Of Europe nuclear medicine data to support client advisory work, competitive benchmarking, and market assessment reports for healthcare stakeholders across the region.

    Key Companies in the Rest Of Europe Nuclear Medicine Market

    CompanyHQOwnershipStrongest segments
    BIOMERIEUX S.A.FrancePublic CompanySPECT,PET,Beta Emitters,
    CARL ZEISS AGGermanyPublic CompanyPET (F-18),SPECT (Tc-99m),
    ATS AUTOMATION TOOLING SYSTEMS INCCanadaPublic CompanySPECT,PET,Brachytherapy,
    BRUKER CORPORATIONUnited StatesPublic CompanyPET,SPECT,Beta Emitters,
    SHIMADZU CORPORATIONJapanPublic CompanyPET (F-18),SPECT (Tc-99m),Alpha Emitters,
    VARIAN MEDICAL SYSTEMS, INCUnited StatesPrivate CompanyBrachytherapy,Linear Accelerators,Software Solutions,
    LEONI AGGermanyPrivate CompanyPET Systems,SPECT Systems,Beta Emitters,
    PFIZERUnited StatesPublic CompanyPET (F-18),Beta Emitters (Y-90, Lu-177),SPECT (Tc-99m),
    ELEKTA ABSwedenPublic CompanyBrachytherapy,Linear Accelerators,Stereotactic Radiosurgery,
    NOVARTIS AGSwitzerlandPublic CompanyBeta Emitters,SPECT,Alpha Emitters,
    LANTHEUS HOLDINGS, INC.United StatesPublic CompanyPET,SPECT,Beta Emitters,
    GE HEALTHCAREUnited StatesPublic CompanySPECT,PET,Brachytherapy,
    TELIX PHARMACEUTICALS LIMITEDAustraliaPublic CompanyPET Imaging,Therapeutics,Manufacturing Solutions,
    SIEMENS HEALTHINEERSGermanyPublic CompanyPET,SPECT,Beta Emitters,
    CHINA ISOTOPE & RADIATION CORPORATIONChinaPublic CompanySPECT,PET,Beta Emitters,
    BAYER AGGermanyPublic CompanySPECT,PET,Alpha Emitters,
    CARDINAL HEALTHUnited StatesPublic CompanySPECT,PET,Beta Emitters,

    BIOMERIEUX S.A.

    bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.

    CARL ZEISS AG

    Carl Zeiss AG is a German public company founded in 1846 with 5,798 employees. The company specializes in optical systems and precision instruments.

    ATS AUTOMATION TOOLING SYSTEMS INC

    ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 with 7,000 employees. The company provides automation and tooling solutions.

    BRUKER CORPORATION

    Bruker Corporation is a United States public company founded in 1960 with 11,085 employees. The company manufactures scientific instruments and analytical solutions.

    SHIMADZU CORPORATION

    Shimadzu Corporation is a Japanese public company founded in 1875 with 14,649 employees. The company manufactures analytical and scientific instruments.

    VARIAN MEDICAL SYSTEMS, INC

    Varian Medical Systems, Inc. is a United States private company founded in 1948 with 10,000 employees. The company specializes in medical devices and radiation oncology solutions.

    LEONI AG

    Leoni AG is a German private company founded in 1569 with 95,090 employees. The company manufactures cables, wiring systems, and related products.

    PFIZER

    Pfizer is a United States public company founded in 1849 with 75,000 employees. The company is a major pharmaceutical manufacturer and developer.

    ELEKTA AB

    Elekta AB is a Swedish public company founded in 1972 with 4,353 employees. The company specializes in radiation therapy and radiosurgery solutions.

    NOVARTIS AG

    Novartis AG is a Swiss public company founded in 1996 with 75,267 employees. The company is a leading pharmaceutical and healthcare company.

    LANTHEUS HOLDINGS, INC.

    Lantheus Holdings, Inc. is a United States public company founded in 1956 with 1,193 employees. The company develops diagnostic imaging agents and radiopharmaceuticals.

    GE HEALTHCARE

    GE Healthcare is a United States public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.

    TELIX PHARMACEUTICALS LIMITED

    Telix Pharmaceuticals Limited is an Australian public company founded in 2015 with 1,152 employees. The company develops diagnostic and therapeutic radiopharmaceuticals.

    SIEMENS HEALTHINEERS

    Siemens Healthineers is a German public company founded in 1896 with 72,369 employees. The company provides medical imaging, diagnostics, and healthcare solutions.

    CHINA ISOTOPE & RADIATION CORPORATION

    China Isotope & Radiation Corporation is a Chinese public company founded in 1983 with 3,578 employees. The company operates in the isotope and radiation sector.

    BAYER AG

    Bayer AG is a German public company founded in 1863 with 87,757 employees. The company operates in pharmaceuticals, crop science, and consumer health.

    CARDINAL HEALTH

    Cardinal Health is a United States public company founded in 1979 with 55,392 employees. The company is a healthcare services and products distributor.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise market valuation ($523.4M in 2025) and verified growth projections (15.1% CAGR) specific to Rest Of Europe, enabling accurate financial forecasting and investment decision-making for regional expansion strategies.
    • Regional Competitive Intelligence : Understand Rest Of Europe's unique market dynamics, competitive landscape, and country-specific variations that differ from global trends, providing strategic advantages for market entry and positioning decisions.
    • Demographic & Clinical Insights : Access detailed analysis of aging populations and chronic disease prevalence driving nuclear medicine demand across Rest Of Europe, supporting targeted marketing and product development aligned with regional healthcare needs.
    • Investment & Partnership Opportunities : Identify high-growth segments and healthcare infrastructure investment trends across Rest Of Europe, enabling strategic partnerships, facility development, and technology deployment in the most promising markets.
    • Regulatory & Reimbursement Guidance : Gain insights into Rest Of Europe's diverse regulatory frameworks and reimbursement models across different countries, reducing market entry risks and accelerating commercialization timelines for nuclear medicine solutions.

    Frequently asked questions

    What is the current size of Rest Of Europe's nuclear medicine market?

    Rest Of Europe's nuclear medicine market is valued at $523.4 million in 2025 and is projected to reach $1,057.3 million by 2030.

    What is the expected growth rate for Rest Of Europe's nuclear medicine market?

    Rest Of Europe's nuclear medicine market is expected to grow at a compound annual growth rate (CAGR) of 15.1% from 2025 to 2030.

    What are the main drivers of growth in Rest Of Europe's nuclear medicine market?

    Key drivers include aging populations, rising chronic disease prevalence, modernization of healthcare infrastructure, and increased clinical adoption of PET/SPECT imaging in oncology, cardiology, and neurology.

    Which imaging modalities are most prominent in Rest Of Europe's nuclear medicine market?

    Rest Of Europe's market is dominated by positron emission tomography (PET) and single-photon emission computed tomography (SPECT) systems, with growing investment in hybrid imaging technologies.

    How is Rest Of Europe's regulatory environment supporting nuclear medicine growth?

    Rest Of Europe's regulatory frameworks are increasingly supportive of radiopharmaceutical development, therapeutic applications, and facility modernization, creating favorable conditions for market expansion.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status